Twelve months after revaccination, antibody levels declined but remained significantly higher than baseline in patients with CLL.

Newer-generation Bruton's tyrosine kinase (BTK) inhibitors have found a place in the management of follicular lymphoma, a ...

Neurology experts from UCSF Health presented new clinical research findings and cutting-edge treatment strategies and received distinguished awards recognition at the American Academy of Neurology’s ...

EPALINGES, Switzerland and PARIS, April 22, 2025 /PRNewswire/ — Onward Therapeutics SA, a biotechnology company dedicated to advancing innovative cancer immunotherapies, announced that its subsidiary, ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

胰腺癌（PDAC）的免疫治疗效果不佳，肿瘤微环境（TME）是重要原因。为探究 TME 中 CD20 + B 细胞的临床意义，福建医科大学附属第一医院等机构的研究人员分析 45 例 PDAC 患者的切片。结果显示，侵袭前沿（IF）的 B 细胞分布特征与患者预后相关。该研究为胰腺癌预后评估提供新视角 129 。

Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from Egypt suggests.

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile in adult patients with generalized myasthenia gravis, offering a promising ...

LONDON, UK I April 17, 2025 I GSK plc (LSE/NYSE: GSK) today announced the authorisation of Blenrep by the Medicines and Healthcare products Regulatory Agency ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of ...

The ENHANCE Phase 3b clinical trial is evaluating the safety and efficacy of a modified treatment regimen of Briumvi for ...

Lyell Immunopharma (LYEL) announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy, RMAT, ...